Drug profile · INN
teprotumumab
TEPEZZA
teprotumumab (TEPEZZA) is a insulin-like growth factor i receptor antagonist.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AG13
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — teprotumumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
teprotumumab (TEPEZZA) is a insulin-like growth factor i receptor antagonist.
Key facts
INN teprotumumab
Brand TEPEZZA
Mechanism Insulin-like growth factor I receptor antagonist
Target Insulin-like growth factor 1 receptor
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AG13
Mechanism of action
Insulin-like growth factor I receptor antagonist
Primary target: Insulin-like growth factor 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is teprotumumab?
teprotumumab (TEPEZZA) is a insulin-like growth factor i receptor antagonist.
What is the brand name for teprotumumab?
TEPEZZA is a marketed brand name for teprotumumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.